{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:06:21Z","timestamp":1770253581724,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Federation of Social Sciences Doctoral Program","award":["2024BS094"],"award-info":[{"award-number":["2024BS094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00705-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:52:59Z","timestamp":1767865979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiatai","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanglin","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"1","key":"705_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13104-020-05243-7","volume":"13","author":"M Bagheri","year":"2020","unstructured":"Bagheri M, Vosoughi T, Hosseinzadeh M, Saki N. Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes. 2020;13(1):412.","journal-title":"BMC Res Notes"},{"issue":"5","key":"705_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000514071","volume":"144","author":"P Langerbeins","year":"2021","unstructured":"Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol. 2021;144(5):508\u201318.","journal-title":"Acta Haematol"},{"issue":"2","key":"705_CR3","first-page":"185","volume":"18","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, et al. Chronic lymphocytic Leukemia\/Small lymphocytic Lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(2):185\u2013217.","journal-title":"J Natl Compr Canc Netw"},{"key":"705_CR4","doi-asserted-by":"crossref","unstructured":"Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T cell defects and immunotherapy in chronic lymphocytic leukemia. Cancers (Basel). 2021;13(13).","DOI":"10.3390\/cancers13133255"},{"issue":"10","key":"705_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00018-022-04540-7","volume":"79","author":"M Galasso","year":"2022","unstructured":"Galasso M, Dalla Pozza E, Chignola R, Gambino S, Cavallini C, Quaglia FM, et al. The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia. Cell Mol Life Sci. 2022;79(10):521.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"705_CR6","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","volume":"42","author":"MS Davids","year":"2020","unstructured":"Davids MS, Waweru C, Le Nouveau P, Padhiar A, Singh G, Abhyankar S, et al. Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: A systematic review and network Meta-analysis. Clin Ther. 2020;42(10):1955\u201374. e15.","journal-title":"Clin Ther"},{"issue":"26","key":"705_CR7","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328.","journal-title":"N Engl J Med"},{"issue":"9","key":"705_CR8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus Chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188\u2013200.","journal-title":"Lancet Oncol"},{"issue":"4","key":"705_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","volume":"11","author":"N Timofeeva","year":"2021","unstructured":"Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021;11(4):79.","journal-title":"Blood Cancer J"},{"issue":"4","key":"705_CR10","doi-asserted-by":"publisher","first-page":"e192249","DOI":"10.1001\/jamanetworkopen.2019.2249","volume":"2","author":"AC Raldow","year":"2019","unstructured":"Raldow AC, Chen AB, Russell M, Lee PP, Hong TS, Ryan DP, et al. Cost-effectiveness of Short-Course radiation therapy vs Long-Course chemoradiation for locally advanced rectal cancer. JAMA Netw Open. 2019;2(4):e192249.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"705_CR11","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1590\/1413-812320141910.02402013","volume":"19","author":"PC de Soarez","year":"2014","unstructured":"de Soarez PC, Soares MO, Novaes HM. [Decision modeling for economic evaluation of health technologies]. Cien Saude Colet. 2014;19(10):4209\u201322.","journal-title":"Cien Saude Colet"},{"issue":"11","key":"705_CR12","first-page":"1532","volume":"27","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, et al. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the united States. J Manag Care Spec Pharm. 2021;27(11):1532\u201344.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"705_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Chai X, Xie J, Yin L, Nie X, Montez M, et al. Cost-Effectiveness analysis of venetoclax in combination with Azacitidine versus Azacitidine monotherapy in patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: from a US third party payer perspective. PharmacoEconomics. 2022;40(8):777\u201390.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"705_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2753.2008.01033.x","volume":"15","author":"H Fukuda","year":"2009","unstructured":"Fukuda H, Imanaka Y. Assessment of transparency of cost estimates in economic evaluations of patient safety programmes. J Eval Clin Pract. 2009;15(3):451\u20139.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"705_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12920-021-01012-y","volume":"14","author":"TL Griffen","year":"2021","unstructured":"Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, et al. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. BMC Med Genomics. 2021;14(1):171.","journal-title":"BMC Med Genomics"},{"issue":"4","key":"705_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jval.2022.11.002","volume":"26","author":"N Do","year":"2023","unstructured":"Do N, Thielen FW. Cost-Effectiveness of venetoclax plus obinutuzumab versus Chlorambucil plus obinutuzumab for the First-Line treatment of adult patients with chronic lymphocytic leukemia: an extended societal view. Value Health. 2023;26(4):477\u201386.","journal-title":"Value Health"},{"issue":"12","key":"705_CR17","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1080\/03007995.2022.2133468","volume":"38","author":"LA Leslie","year":"2022","unstructured":"Leslie LA, Gangan N, Tan H, Huang Q. Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. Curr Med Res Opin. 2022;38(12):2149\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"705_CR18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/13696998.2020.1796360","volume":"23","author":"H Cranmer","year":"2020","unstructured":"Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176\u201385.","journal-title":"J Med Econ"},{"key":"705_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","volume":"11","author":"MW Hoyle","year":"2011","unstructured":"Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.","journal-title":"BMC Med Res Methodol"},{"key":"705_CR20","unstructured":"Latimer NR. Survival Analysis For Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient-Level Data [Internet]. London: National Institute for Health and Care Excellence (NICE); 2013 Mar. NICE DSU Technical Support Document No. 14. PMID: 27905716."},{"issue":"5","key":"705_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/10635150490522304","volume":"53","author":"D Posada","year":"2004","unstructured":"Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol. 2004;53(5):793\u2013808.","journal-title":"Syst Biol"},{"issue":"7","key":"705_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40273-018-0630-9","volume":"36","author":"IA Tikhonova","year":"2018","unstructured":"Tikhonova IA, Huxley N, Snowsill T, Crathorne L, Varley-Campbell J, Napier M, et al. Economic analysis of First-Line treatment with cetuximab or panitumumab for RAS Wild-Type metastatic colorectal cancer in England. PharmacoEconomics. 2018;36(7):837\u201351.","journal-title":"PharmacoEconomics"},{"key":"705_CR23","unstructured":"R G. China health statistical yearbook 2020: Springer Nature; 2020."},{"issue":"5","key":"705_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518\u201328.","journal-title":"Value Health"},{"key":"705_CR25","volume-title":"Cost-effectiveness in health and medicine","year":"2016","unstructured":"Neumann PJGT, Russell LB, Sanders GD, Siegel JE, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2016."},{"issue":"6","key":"705_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11655-014-1749-y","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Wang ZF, Xie YM, Zhang W, Liao X, Chang YP, et al. Guideline for postmarketing Chinese medicine Pharmacoeconomic evaluation. Chin J Integr Med. 2015;21(6):473\u201380.","journal-title":"Chin J Integr Med"},{"key":"705_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.leukres.2016.09.005","volume":"50","author":"HM Blommestein","year":"2016","unstructured":"Blommestein HM, de Groot S, Aarts MJ, Vemer P, de Vries R, van Abeelen AF, et al. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in the Netherlands. Leuk Res. 2016;50:37\u201345.","journal-title":"Leuk Res"},{"key":"705_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O\u2019Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","journal-title":"Health Qual Life Outcomes"},{"key":"705_CR29","unstructured":"Platform DCP. http:\/\/www.ynyyzb.com.cn\/detail.html?infoId=22112&CatalogId=3 2023 [."},{"key":"705_CR30","doi-asserted-by":"publisher","first-page":"732912","DOI":"10.3389\/fphar.2021.732912","volume":"12","author":"H Cai","year":"2021","unstructured":"Cai H, Xu B, Li N, Zheng B, Zheng Z, Liu M. Cost-Effectiveness analysis of camrelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma. Front Pharmacol. 2021;12:732912.","journal-title":"Front Pharmacol"},{"key":"705_CR31","doi-asserted-by":"publisher","first-page":"1081912","DOI":"10.3389\/fphar.2022.1081912","volume":"13","author":"T Tian","year":"2022","unstructured":"Tian T, Commentary. A GSH\/CB dual-controlled self-assembled nanomedicine for high-efficacy doxorubicin-resistant breast cancer therapy. Front Pharmacol. 2022;13:1081912.","journal-title":"Front Pharmacol"},{"key":"705_CR32","doi-asserted-by":"publisher","first-page":"1146531","DOI":"10.3389\/fpubh.2023.1146531","volume":"11","author":"C Yina","year":"2023","unstructured":"Yina C, Pengcheng L, Haomiao N, Yang C. An empirical study of the impact of generic drug competition on drug market prices in China. Front Public Health. 2023;11:1146531.","journal-title":"Front Public Health"},{"issue":"8","key":"705_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/CM9.0000000000001811","volume":"135","author":"RP Gale","year":"2022","unstructured":"Gale RP. Chronic lymphocytic leukemia in China. Chin Med J (Engl). 2022;135(8):883\u20136. https:\/\/doi.org\/10.1097\/CM9.0000000000001811. PMID: 34636775; PMCID: PMC9276188.","journal-title":"Chin Med J (Engl)"},{"key":"705_CR34","unstructured":"(ZIN) DNHCI. Package advice venetoclax (Venclyxto\u00ae) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL).https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2020\/11\/16\/venetoclax-venclyxto.: https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2020\/11\/16\/venetoclax-venclyxto; [."},{"issue":"1","key":"705_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12913-022-07791-z","volume":"22","author":"J Espin","year":"2022","unstructured":"Espin J, Spacirova Z, Rovira J, Epstein D, Olry de Labry Lima A, Garcia-Mochon L. Development of the European healthcare and social cost database (EU HCSCD) for use in economic evaluation of healthcare programs. BMC Health Serv Res. 2022;22(1):405.","journal-title":"BMC Health Serv Res"},{"key":"705_CR36","unstructured":"Rouse WB, Serban N. Understanding and managing the complexity of healthcare. MIT Press; 2014."},{"issue":"3","key":"705_CR37","doi-asserted-by":"publisher","first-page":"e001418","DOI":"10.1136\/bmjgh-2019-001418","volume":"4","author":"T Butt","year":"2019","unstructured":"Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Glob Health. 2019;4(3):e001418.","journal-title":"BMJ Glob Health"},{"issue":"10","key":"705_CR38","doi-asserted-by":"publisher","first-page":"e0258274","DOI":"10.1371\/journal.pone.0258274","volume":"16","author":"X Guo","year":"2021","unstructured":"Guo X, Zhang J, Xu Z, Cong X, Zhu Z. The efficiency of provincial government health care expenditure after china\u2019s new health care reform. PLoS ONE. 2021;16(10):e0258274.","journal-title":"PLoS ONE"},{"issue":"1","key":"705_CR39","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1186\/s12889-021-12248-9","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Lin Z, Li LA, Li J, Wang Y, Pan Y, et al. Ten years of china\u2019s new healthcare reform: a longitudinal study on changes in health resources. BMC Public Health. 2021;21(1):2272.","journal-title":"BMC Public Health"},{"key":"705_CR40","doi-asserted-by":"publisher","first-page":"793165","DOI":"10.3389\/fsoc.2022.793165","volume":"7","author":"K Muehlfeld","year":"2022","unstructured":"Muehlfeld K, Wang M. Intellectual property rights in China-A literature review on the public\u2019s perspective. Front Sociol. 2022;7:793165.","journal-title":"Front Sociol"},{"key":"705_CR41","doi-asserted-by":"crossref","unstructured":"Lu MQBS, Tan Y, Xu C. Pharmaceutical Intellectual Property Rights in China. Approaching China\u2019s Pharmaceutical Market. Springer Nature; 2015.","DOI":"10.1007\/978-3-319-15576-0_2"},{"issue":"1","key":"705_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12913-021-06130-y","volume":"21","author":"SM Lee","year":"2021","unstructured":"Lee SM, Kim HJ, Suh D, Joung KI, Kim ES, Back HJ, et al. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. BMC Health Serv Res. 2021;21(1):126.","journal-title":"BMC Health Serv Res"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00705-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:48:36Z","timestamp":1770205716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00705-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00705-w","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}